Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19 (LILIADE-COVID)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04357444|
Recruitment Status : Recruiting
First Posted : April 22, 2020
Last Update Posted : November 20, 2020
|Condition or disease||Intervention/treatment||Phase|
|COVID 19||Drug: 1: ILT101 Drug: 2: Placebo Comparator||Phase 2|
About 25% of hospitalized patients with SARS-CoV2 infection presented life-threatening respiratory conditions. Of these, 60% met ARDS criteria leading to death in 25% to 63% of the cases. SARS-CoV2-related ARDS is caused by a massive inflammatory cell infiltration leading to dysregulated cytokine/chemokine responses with lung immunopathological changes. To date, there is no treatment available.
Regulatory T cells (Treg) are a subpopulation of CD4+ T cells playing a crucial role in the control of immune responses, in part by preventing excessive inflammation. Depletion of Treg cells in models of lung infection or after berylium exposure exacerbated lung inflammation. In contrast, a beneficial role for Treg during early ARDS and its resolution has been observed.
Low-dose interleukin 2 (Ld-IL2) is the first therapy driving Treg-specific expansion and activation. Ld-IL2 was successfully tested in a wide range of preclinical models of inflammatory diseases, including beryllium-induced lung inflammation. Moreover, Ld-IL2 has been shown to be safe and free of serious adverse events when administered in patients with various autoimmune diseases. Importantly, in our previous work, we observed only very low concentrations of IL-2 in the blood (0.1 pg/mL [0.0-2.0]) as well as in the BAL supernatant (0.8 pg/mL [0.4-1.3]) collected from patients during the early phase of ARDS, suggesting that additional IL-2 could be beneficial for Treg expansion/activation.
Our objective is therefore to investigate the therapeutic benefit of Ld-IL2 as a Treg inducer for controlling SARS-CoV2-related ARDS.
After admission of patients to the intensive care unit at one of the recruiting centers, the eligibility criteria will be checked by the investigating physician and participation in the study will be proposed to the patient or parent/family member/trusted person. If the patient is unable to consent and there is no parent/family member/trusted person, the patient may be included in the emergency procedure.
After inclusion (J0), the patient will be randomized to one of the 2 treatment arms (low dose IL-2 or placebo).
The experimental treatment will be daily administered to the patient from D1 to D10.
The patient will be monitored daily until D28 during hospitalization.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19|
|Actual Study Start Date :||October 23, 2020|
|Actual Primary Completion Date :||November 2, 2020|
|Estimated Study Completion Date :||February 23, 2021|
Experimental: 1: ILT101
ILT-101 in Subcutaneous route
Drug: 1: ILT101
Subcutaneous injections, once-daily administration for 10 consecutive days.
Placebo Comparator: 2: Placebo Comparator
Placebo in subcutaneous injections every day during 10 days
Drug: 2: Placebo Comparator
placebo in Subcutaneous route
- The PaO2/FiO2 ratio at D11 [ Time Frame: at Day11 ]
- Changes in Tregs between Baseline and Day 7 (expressed in %) [ Time Frame: at Day0 and Day7 ]
- Number of days alive with oxygen therapy within 28 days [ Time Frame: at Day28 ]
- Maximal oxygen rate within 28 days [ Time Frame: at Day28 ]
- Number of days alive free of invasive or non-invasive ventilation within 28 days [ Time Frame: At Day28 ]
- Number of days alive outside ICU within 28 days [ Time Frame: at Day28 ]
- Number of days alive outside hospital within 28 days [ Time Frame: at Day28 ]
- Time (in days) from randomization to death [ Time Frame: through study completion at day 28 ]
- Mortality rate at D28 [ Time Frame: at Day28 ]
- Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7) [ Time Frame: at Day0 and Day7 or at the time of discharge ]
- Use of antibiotics for respiratory (proved or suspected) infection within 28 days [ Time Frame: at Day28 ]
- Number of prone positioning sessions [ Time Frame: throughout the follow up period at day 28 ]
- Changes in Tregs during the different visits between baseline and day 28 [ Time Frame: at Day0, 5, 7, 11, 14 and Day28 ]
- Cytokines analysis on plasma samples at Day 0, 7 and 14 [ Time Frame: at Day 0, 7 and 14 ]To evaluate selected immune and inflammatory markers: Serum concentrations of cytokines and soluble factors related to the immune response and inflammatory processes will be evaluated and compare to baseline by multiplex immunoprofiling to analyse a larger number of molecules including at least IFNα2, IFNγ, IL-1α, IL-1β, IL-1RA, IL-2, IL-6, IL-8, IL-10, IL-17, TNFα, TNFβ, VEGF-A, TGF-beta, S-RAGE, SP-A, SP-D, Angiopoétine 1 and KGF.
- Tregs numbers during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection. [ Time Frame: at Day0, 5, 7, 11, 14 and Day28 ]
- Tregs percentages during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection. [ Time Frame: at Day0, 5, 7, 11, 14 and Day28 ]
- Deep Immunophenotyping of Cellular components in blood samples at Day 0, 7, and 14 [ Time Frame: at Day0, 7 and Day14 ]Cellular components will be analysed by flow cytometry covering (i) most of the innate and adaptive immune cells including Tregs, T helper cell subsets including follicular helper cells, B cell subsets, NK cell subsets, (ii) the associated relevant markers of activation/function/differentiation, tissue migration, as well as (iii) unconventional lymphoid cells (NKT/MAIT, innate lymphoid cells), myeloid-derived suppressor cells, classical and non-classical monocytes and dendritic cells (mDC1/2, pDC).
- T cell repertoire on Treg, after sorting from blood at Day 7 and Day 14 and compared to baseline [ Time Frame: at Day0, 7 and Day14 ]
- T cell repertoire on Teff (CD4 and CD8) after sorting from blood at Day 7 and Day 14 and compared to baseline [ Time Frame: at Day0, 7 and Day14 ]
- Single cells sequencing will be performed in BAL at Day 7 and Day 14 and compared to baseline. [ Time Frame: at Day0, 7 and Day14 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04357444
|Contact: Jean-Michel CONSTANTIN, MD, PhD||+33(0) 1 42 16 00 00||Jeanfirstname.lastname@example.org|
|Service Anesthésie Réanimation - Groupe Hospitalier Pitié-Salpêtrière||Recruiting|
|Paris, France, 75013|
|Contact: Jean-Michel CONSTANTIN, MD, PhD +33(0) 1 42 16 00 00 Jeanemail@example.com|
|Principal Investigator:||Jean-Michel CONSTANTIN||Assistance Publique - Hôpitaux de Paris|